Veradermics, Incorporated
Financials
Valuation Metrics
Veradermics, Incorporated's Market Cap is $5.41B. Ranked #1222 of 3,118 in US market (top 39%), #825 of 1,644 on NYSE (top 50%), #69 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 26%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.41B | US#1,222/3,118 Sec#69/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-93M | US—/3,118 Sec—/265 |
| Total Assets | $826M | US#2,553/3,118 Sec#117/265 |
| Net Assets | $814M | US#1,900/3,118 Sec#78/265 |
| Employees | 37 | US#2,723/3,118 Sec#214/265 |
| Value | ||
| P/B | 6.64x | US#2,464/3,118 Sec#173/265 |
| FCF Yield | -1.45% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -11.39% | US#2,380/3,118 Sec#83/265 |
| ROA | -11.22% | US#2,674/3,118 Sec#103/265 |
| Financial Health | ||
| Debt Ratio | 1.49% | US#9/3,118 Sec#2/265 |
| Total Debt | $428000.00 | US#2,982/3,118 Sec#252/265 |
| FCF | $-78M | US#2,589/3,118 Sec#132/265 |
| Cash | $319M | US#1,363/3,118 Sec#79/265 |
| Current Ratio | 70.53x | US#45/3,118 Sec#3/265 |
| Performance | ||
| 1M Return | 10.81% | US#420/3,118 Sec#27/265 |
| From 52W High | -11.73% | US#384/3,118 Sec#28/265 |
| 1Y MDD | -24.84% | US#938/3,118 Sec#37/265 |
| Trading | ||
| Volume | 562,439 shares | US#2,206/3,118 Sec#214/265 |
| Trading Value | $75M | US#1,205/3,118 Sec#70/265 |
| Per Share | ||
| EPS | $-2.22 | US—/3,118 Sec—/265 |
| BPS | $19.47 | US#1,257/3,118 Sec#29/265 |
Company Info
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.